{"id":952862,"date":"2026-04-20T08:38:01","date_gmt":"2026-04-20T12:38:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-reports-positive-preclinical-data-for-aktx-101-demonstrating-differentiated-cytotoxicity-for-first-in-class-trop2-adc-payload-targeting-rna-splicing\/"},"modified":"2026-04-20T08:38:01","modified_gmt":"2026-04-20T12:38:01","slug":"akari-therapeutics-reports-positive-preclinical-data-for-aktx-101-demonstrating-differentiated-cytotoxicity-for-first-in-class-trop2-adc-payload-targeting-rna-splicing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-reports-positive-preclinical-data-for-aktx-101-demonstrating-differentiated-cytotoxicity-for-first-in-class-trop2-adc-payload-targeting-rna-splicing\/","title":{"rendered":"Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing"},"content":{"rendered":"
\n

\n Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models<\/em>\n <\/p>\n

\n Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance<\/em>\n <\/p>\n

\n Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033<\/em>
\n
\n 1<\/em>
\n <\/sup>\n <\/p>\n

TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research (AACR) Annual Meeting 2026. Access the poster here<\/a>.<\/p>\n

Unlike current TROP2-targeting ADCs that use Topoisomerase I Inhibitor (Inh.) payloads, AKTX-101 has the potential to address resistance to Topoisomerase I Inh. ADCs and contribute to durable anti-tumor efficacy due to the payload\u2019s unique cytotoxic and immune-activating mechanisms of action.<\/p>\n

The preclinical data compares the performance of AKTX-101 versus TROP2 ADCs with Topoisomerase I Inh. payloads in the killing of different cancer types driven by different cancer genes (oncogenes). AKTX-101\u2019s ability to kill cancer cells at lower concentrations vs. TROP2 ADCs using Topoisomerase I Inh. payloads suggests that AKTX-101 is a more potent drug.<\/p>\n

The preclinical data was published recently as an abstract<\/a> in Cancer Research<\/em>, an AACR journal.<\/p>\n

Here, AKTX-101 demonstrated greater potency and\/or greater maximum cancer cell killing relative to TROP2 ADC Topoisomerase I Inh. payloads in cancers of the bladder, lung and breast. AKTX-101 demonstrated sub-nanomolar potency in all bladder cancer lines tested, a key tumor in which first-in-human clinical trials for AKTX-101 are planned.<\/p>\n

AKTX-101 also demonstrated sub-nanomolar potency in several non-small cell lung cancer cell lines driven by EGFR, BRAF, and SMARCA4, as well as potent cell killing in HER2 breast cancer cell lines with inherent resistance to Topoisomerase I Inh. ADCs such as trastuzumab deruxtecan (ENHERTU\u2122).<\/p>\n

\u201cThese data represent a significant step forward for our lead program, AKTX-101, and reinforce our belief that a differentiated ADC payload with multiple mechanisms of action has the potential to meaningfully improve outcomes for patients with TROP2-expressing cancers,\u201d commented Satyajit K. Mitra, Ph.D., Head of Oncology Research and Development at Akari Therapeutics. \u201cWe are seeing preclinical superior AKTX-101 potency and activity as compared to TROP2 ADCs using Topoisomerase I inhibitor payloads in bladder, lung, and breast cancer models. Together, these findings show that AKTX-101 has strong potential for targeting a broad range of cancer tumors and sub-types with superior cytotoxicity than current TROP2 ADCs that use Topoisomerase I Inhibitor payloads.\u201d<\/p>\n

The TROP2 ADC class continues to emerge in terms of its potential, with revenue projections expected to reach ~$12B or greater by 2033 based on current and future entrants. Akari believes that AKTX-101, with its novel RNA splicing modulator payload, can grow this class further by addressing multiple solid tumors where TROP2 is overexpressed including bladder, lung, breast, pancreatic, head and neck, and others.<\/p>\n

\n Key AKTX-101 Data Presented at AACR Highlights:<\/strong>\n <\/p>\n